A compendium answering 150 questions on COVID-19 and SARS-CoV-2

Carmen Riggioni, Pasquale Comberiati, Mattia Giovannini, Ioana Agache, Mübeccel Akdis, Magna Alves-Correia, Josep M Antó, Alessandra Arcolaci, Ahmet Kursat Azkur, Dilek Azkur, Burcin Beken, Cristina Boccabella, Jean Bousquet, Heimo Breiteneder, Daniela Carvalho, Leticia De Las Vecillas, Zuzana Diamant, Ibon Eguiluz-Gracia, Thomas Eiwegger, Stefanie EyerichWytske Fokkens, Ya-Dong Gao, Farah Hannachi, Sebastian L Johnston, Marek Jutel, Aspasia Karavelia, Ludger Klimek, Beatriz Moya, Kari C Nadeau, Robyn O'Hehir, Liam O'Mahony, Oliver Pfaar, Marek Sanak, Jürgen Schwarze, Milena Sokolowska, María J Torres, Willem van de Veen, Menno C van Zelm, De Yun Wang, Luo Zhang, Rodrigo Jiménez-Saiz, Cezmi A Akdis

Research output: Journal article (peer-reviewed)Review article

87 Citations (Scopus)


In December 2019, China reported the first cases of the coronavirus disease 2019 (COVID-19). This disease, caused by the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), has developed into a pandemic. To date, it has resulted in ~9 million confirmed cases and caused almost 500 000 related deaths worldwide. Unequivocally, the COVID-19 pandemic is the gravest health and socioeconomic crisis of our time. In this context, numerous questions have emerged in demand of basic scientific information and evidence-based medical advice on SARS-CoV-2 and COVID-19. Although the majority of the patients show a very mild, self-limiting viral respiratory disease, many clinical manifestations in severe patients are unique to COVID-19, such as severe lymphopenia and eosinopenia, extensive pneumonia, a "cytokine storm" leading to acute respiratory distress syndrome, endothelitis, thromboembolic complications, and multiorgan failure. The epidemiologic features of COVID-19 are distinctive and have changed throughout the pandemic. Vaccine and drug development studies and clinical trials are rapidly growing at an unprecedented speed. However, basic and clinical research on COVID-19-related topics should be based on more coordinated high-quality studies. This paper answers pressing questions, formulated by young clinicians and scientists, on SARS-CoV-2, COVID-19, and allergy, focusing on the following topics: virology, immunology, diagnosis, management of patients with allergic disease and asthma, treatment, clinical trials, drug discovery, vaccine development, and epidemiology. A total of 150 questions were answered by experts in the field providing a comprehensive and practical overview of COVID-19 and allergic disease.

Original languageEnglish
Pages (from-to)2503-2541
Number of pages39
JournalAllergy: European Journal of Allergy and Clinical Immunology
Issue number10
Publication statusPublished - 01 Oct 2020
Externally publishedYes


  • Betacoronavirus/immunology
  • COVID-19
  • Coronavirus Infections/complications
  • Humans
  • Hypersensitivity/complications
  • Pandemics
  • Pneumonia, Viral/complications
  • SARS-CoV-2


Dive into the research topics of 'A compendium answering 150 questions on COVID-19 and SARS-CoV-2'. Together they form a unique fingerprint.

Cite this